6-KThe Wire
HUTCHMED (China) Ltd files 6-K
Filed Apr 29, 2026 · 2mo ago · Accession 0001648257-26-000026
Plain English
Hutchmed (China) Limited announced that the New Drug Application for sovleplenib for the treatment of warm autoimmune hemolytic anemia has been accepted for review with priority review status in China. This designation is a significant step towards potential approval of the drug.
Filing details
- Company
- HUTCHMED (China) Ltd
- Ticker
- HCM
- CIK
- 1648257
- Form type
- 6-K
- Filing date
- Apr 29, 2026
- Report date
- Apr 29, 2026
- Document
- hcm-20260429x6k.htm
- Size
- 56 KB